Mainz Biomed N.V. (MYNZ)
- Previous Close
0.8692 - Open
0.8810 - Bid 0.7968 x 100
- Ask 0.8392 x 100
- Day's Range
0.7951 - 0.8900 - 52 Week Range
0.5500 - 5.8000 - Volume
219,273 - Avg. Volume
142,111 - Market Cap (intraday)
17.947M - Beta (5Y Monthly) 0.28
- PE Ratio (TTM)
-- - EPS (TTM)
-1.6200 - Earnings Date Aug 12, 2024 - Aug 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.00
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.
mainzbiomed.com65
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: MYNZ
Performance Overview: MYNZ
Trailing total returns as of 6/3/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MYNZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MYNZ
Valuation Measures
Market Cap
19.02M
Enterprise Value
19.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
15.77
Price/Book (mrq)
5.85
Enterprise Value/Revenue
21.64
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-93.42%
Return on Equity (ttm)
-303.20%
Revenue (ttm)
895.48k
Net Income Avi to Common (ttm)
-26.3M
Diluted EPS (ttm)
-1.6200
Balance Sheet and Cash Flow
Total Cash (mrq)
7.07M
Total Debt/Equity (mrq)
228.39%
Levered Free Cash Flow (ttm)
-13.61M
Research Analysis: MYNZ
Company Insights: MYNZ
MYNZ does not have Company Insights